Skeletal muscle mass is not merely a determinant of physical strength and mobility; it is a critical reservoir of metabolic health, immune function, and longevity. In recent years, the field has undergone a paradigm shift, moving beyond traditional descriptions of hypertrophy and atrophy toward a molecularly precise understanding of how muscle mass is regulated, measured, and restored. This review highlights key advances in the molecular regulation of muscle mass, emerging technologies for quantification, and therapeutic strategies that are reshaping the clinical landscape.

Molecular mechanisms: Beyond the IGF-1/Akt/mTOR axis

For decades, the insulin-like growth factor 1 (IGF-1)/Akt/mTOR signaling cascade has been considered the central anabolic pathway governing skeletal muscle mass. However, recent work has identified additional layers of regulation that offer new therapeutic targets. The ubiquitin-proteasome system (UPS) and autophagy-lysosome pathways remain central to muscle wasting, but the discovery of the muscle-specific ubiquitin ligase MuRF1 and atrogin-1 has enabled the development of selective inhibitors. A 2023 study by Bodine and colleagues demonstrated that small-molecule inhibition of MuRF1 preserves muscle mass in murine models of cachexia without disrupting cardiac function, a persistent concern with earlier proteasome inhibitors.

Equally transformative is the recognition of myostatin and activin A as dominant negative regulators. The approval of bimagrumab, a monoclonal antibody blocking the activin type II receptor (ActRII), has entered phase III trials for sporadic inclusion body myositis and sarcopenia. In a 2024 randomized controlled trial, bimagrumab increased lean body mass by 6.2% over 24 weeks compared to placebo, with significant improvements in stair-climbing power (Rooks et al.,The Lancet, 2024). Importantly, this effect was independent of physical activity, suggesting that pharmacological blockade of the myostatin pathway can bypass exercise resistance in frail populations.

Emerging research has also highlighted the role of extracellular matrix (ECM) remodeling in maintaining skeletal muscle mass. The collagen network, once considered a passive scaffold, is now known to actively transduce mechanical signals via integrins and focal adhesion kinase (FAK). A 2025 study from the University of Melbourne showed that age-related accumulation of cross-linked collagen reduces muscle fiber contractility and satellite cell activation, and that targeted collagenase therapy partially restores muscle mass in aged mice (Klein et al.,Nature Metabolism, 2025). This opens a new avenue for treating sarcopenia not by targeting the muscle cell itself, but its supportive niche.

Technological breakthroughs: High-resolution quantification and imaging

Accurate measurement of skeletal muscle mass has long been hampered by the limitations of dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance, which cannot distinguish between muscle, edema, and intermuscular adipose tissue. Recent advances in quantitative MRI, particularly Dixon-based fat-water separation and diffusion tensor imaging (DTI), now allow for voxel-level mapping of muscle volume, fat infiltration, and microstructural integrity. A landmark 2024 multicenter study validated a 10-minute whole-body MRI protocol that correlates with histological muscle cross-sectional area (r = 0.91) and predicts 5-year fall risk in older adults with 83% accuracy (Cruz-Jentoft et al.,Journal of Cachexia, Sarcopenia and Muscle, 2024).

On the molecular side, the development of stable isotope tracer techniques (e.g., D₂O labeling) has enabled simultaneous measurement of muscle protein synthesis (MPS) and breakdown (MPB) in free-living conditions. This has revealed a surprising finding: in early-stage sarcopenia, MPB is not elevated but MPS is blunted, meaning that therapeutic strategies should focus on anabolic stimulation rather than anti-catabolic interventions. Furthermore, single-nucleus RNA sequencing has identified a population of “pro-fibrotic” mesenchymal progenitors that expand during muscle wasting and secrete ligands that suppress satellite cell differentiation. Targeting these cells with PDGFRα inhibitors has been shown to preserve muscle mass in a 2025 mouse model of Duchenne muscular dystrophy (Wang et al.,Cell Stem Cell, 2025).

Clinical translation: From exercise mimetics to gene editing

Exercise remains the gold standard for preserving skeletal muscle mass, but compliance is poor in elderly and hospitalized patients. The search for “exercise mimetics” has yielded several promising candidates. The most advanced is the AMPK agonist (e.g., AICAR, metformin), but their efficacy in humans is modest. A more recent breakthrough involves the hypoxia-inducible factor 2α (HIF-2α) pathway. A 2024 phase II trial of vadadustat, an HIF-PH inhibitor originally developed for anemia, unexpectedly showed a 3.8% increase in appendicular lean mass in patients with chronic kidney disease, possibly due to enhanced capillary density and nutrient delivery to muscle (Chertow et al.,NEJM, 2024).

Gene editing is also entering the arena. The first-in-human trial of CRISPR-Cas9 therapy for Duchenne muscular dystrophy (CRD-TX-001) reported restoration of dystrophin expression in 12% of muscle fibers at 12 months, with stabilization of muscle mass and function (Olson et al.,Science Translational Medicine, 2025). While still early, this proof-of-concept demonstrates that permanent correction of genetic defects can restore skeletal muscle mass over the long term.

Future outlook

The next decade will likely see the integration of multi-omics profiling to predict individual responses to anabolic interventions. A key challenge is the heterogeneity of muscle wasting – cachexia, sarcopenia, and disuse atrophy share some pathways but differ in their dominant drivers. Machine learning models trained on longitudinal DXA, MRI, and serum proteomics are already achieving 90% accuracy in classifying wasting subtypes, enabling personalized treatment regimens.

Another frontier is the role of the gut-muscle axis. Recent metagenomic studies have identified specific bacterial strains (e.g.,Prevotella copri,Lactobacillus plantarum) that produce short-chain fatty acids capable of stimulating MPS via GPR41/43 receptors. A 2025 randomized trial showed that a synbiotic supplement increased thigh muscle cross-sectional area by 2.1% over 16 weeks in sarcopenic older adults, independent of protein intake (Ticinesi et al.,Clinical Nutrition, 2025). If confirmed, this could offer a low-cost, scalable intervention for populations with limited access to exercise facilities.

Finally, the convergence of wearable sensors and closed-loop drug delivery systems may soon allow real-time modulation of skeletal muscle mass. Implantable microfluidic devices that release myostatin inhibitors in response to accelerometer-detected immobility are in preclinical testing. While ethical and regulatory hurdles remain, the vision of on-demand muscle mass preservation – particularly for astronauts, bedridden patients, and the very old – is becoming tangible.

In summary, the study of skeletal muscle mass has evolved into a multidisciplinary field where molecular biology, imaging, and bioengineering converge. The advances of the past three years alone have moved the needle from descriptive phenotyping to mechanism-based intervention, promising a future where muscle wasting is not an inevitable consequence of aging or disease, but a treatable condition.